Cargando…

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients

Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity. We reviewed all consecutive cases of adult acute lymphoblastic leukemia treated at our institution between 2000 and 2017 and identified therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldoss, Ibrahim, Stiller, Tracey, Tsai, Ni-Chun, Song, Joo Y., Cao, Thai, Bandara, N. Achini, Salhotra, Amandeep, Khaled, Samer, Aribi, Ahmed, Al Malki, Monzr M., Mei, Matthew, Ali, Haris, Spielberger, Ricardo, O’Donnell, Margaret, Snyder, David, Slavin, Thomas, Nakamura, Ryotaro, Stein, Anthony S., Forman, Stephen J., Marcucci, Guido, Pullarkat, Vinod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165794/
https://www.ncbi.nlm.nih.gov/pubmed/29903756
http://dx.doi.org/10.3324/haematol.2018.193599
_version_ 1783359908345806848
author Aldoss, Ibrahim
Stiller, Tracey
Tsai, Ni-Chun
Song, Joo Y.
Cao, Thai
Bandara, N. Achini
Salhotra, Amandeep
Khaled, Samer
Aribi, Ahmed
Al Malki, Monzr M.
Mei, Matthew
Ali, Haris
Spielberger, Ricardo
O’Donnell, Margaret
Snyder, David
Slavin, Thomas
Nakamura, Ryotaro
Stein, Anthony S.
Forman, Stephen J.
Marcucci, Guido
Pullarkat, Vinod
author_facet Aldoss, Ibrahim
Stiller, Tracey
Tsai, Ni-Chun
Song, Joo Y.
Cao, Thai
Bandara, N. Achini
Salhotra, Amandeep
Khaled, Samer
Aribi, Ahmed
Al Malki, Monzr M.
Mei, Matthew
Ali, Haris
Spielberger, Ricardo
O’Donnell, Margaret
Snyder, David
Slavin, Thomas
Nakamura, Ryotaro
Stein, Anthony S.
Forman, Stephen J.
Marcucci, Guido
Pullarkat, Vinod
author_sort Aldoss, Ibrahim
collection PubMed
description Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity. We reviewed all consecutive cases of adult acute lymphoblastic leukemia treated at our institution between 2000 and 2017 and identified therapy-related cases - defined as acute lymphoblastic leukemia preceded by prior exposure to cytotoxic chemotherapy and/or radiation. Of 1022 patients with acute lymphoblastic leukemia, 93 (9.1%) were classified as therapy-related. The median latency for therapy-related acute lymphoblastic leukemia onset was 6.8 years from original diagnosis, and this was shorter for patients carrying the MLL gene rearrangement compared to those with other cytogenetics. When compared to de novo acute lymphoblastic leukemia, therapy-related patients were older (P<0.01), more often female (P<0.01), and had more MLL gene rearrangement (P<0.0001) and chromosomes 5/7 aberrations (P=0.02). Although therapy-related acute lymphoblastic leukemia was associated with inferior 2-year overall survival compared to de novo cases (46.0% vs. 68.1%, P=0.001), prior exposure to cytotoxic therapy (therapy-related) did not independently impact survival in multivariate analysis (HR=1.32; 95% CI: 0.97–1.80, P=0.08). There was no survival difference (2-year = 53.4% vs. 58.9%, P=0.68) between the two groups in patients who received allogenic hematopoietic cell transplantation. In conclusion, therapy-related acute lymphoblastic leukemia represents a significant proportion of adult acute lymphoblastic leukemia diagnoses, and a subset of cases carry clinical and cytogenetic abnormalities similar to therapy-related myeloid neoplasms. Although survival of therapy-related acute lymphoblastic leukemia was inferior to de novo cases, allogeneic hematopoietic cell transplantation outcomes were comparable for the two entities.
format Online
Article
Text
id pubmed-6165794
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ferrata Storti Foundation
record_format MEDLINE/PubMed
spelling pubmed-61657942018-10-04 Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients Aldoss, Ibrahim Stiller, Tracey Tsai, Ni-Chun Song, Joo Y. Cao, Thai Bandara, N. Achini Salhotra, Amandeep Khaled, Samer Aribi, Ahmed Al Malki, Monzr M. Mei, Matthew Ali, Haris Spielberger, Ricardo O’Donnell, Margaret Snyder, David Slavin, Thomas Nakamura, Ryotaro Stein, Anthony S. Forman, Stephen J. Marcucci, Guido Pullarkat, Vinod Haematologica Article Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity. We reviewed all consecutive cases of adult acute lymphoblastic leukemia treated at our institution between 2000 and 2017 and identified therapy-related cases - defined as acute lymphoblastic leukemia preceded by prior exposure to cytotoxic chemotherapy and/or radiation. Of 1022 patients with acute lymphoblastic leukemia, 93 (9.1%) were classified as therapy-related. The median latency for therapy-related acute lymphoblastic leukemia onset was 6.8 years from original diagnosis, and this was shorter for patients carrying the MLL gene rearrangement compared to those with other cytogenetics. When compared to de novo acute lymphoblastic leukemia, therapy-related patients were older (P<0.01), more often female (P<0.01), and had more MLL gene rearrangement (P<0.0001) and chromosomes 5/7 aberrations (P=0.02). Although therapy-related acute lymphoblastic leukemia was associated with inferior 2-year overall survival compared to de novo cases (46.0% vs. 68.1%, P=0.001), prior exposure to cytotoxic therapy (therapy-related) did not independently impact survival in multivariate analysis (HR=1.32; 95% CI: 0.97–1.80, P=0.08). There was no survival difference (2-year = 53.4% vs. 58.9%, P=0.68) between the two groups in patients who received allogenic hematopoietic cell transplantation. In conclusion, therapy-related acute lymphoblastic leukemia represents a significant proportion of adult acute lymphoblastic leukemia diagnoses, and a subset of cases carry clinical and cytogenetic abnormalities similar to therapy-related myeloid neoplasms. Although survival of therapy-related acute lymphoblastic leukemia was inferior to de novo cases, allogeneic hematopoietic cell transplantation outcomes were comparable for the two entities. Ferrata Storti Foundation 2018-10 /pmc/articles/PMC6165794/ /pubmed/29903756 http://dx.doi.org/10.3324/haematol.2018.193599 Text en Copyright © 2018 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
spellingShingle Article
Aldoss, Ibrahim
Stiller, Tracey
Tsai, Ni-Chun
Song, Joo Y.
Cao, Thai
Bandara, N. Achini
Salhotra, Amandeep
Khaled, Samer
Aribi, Ahmed
Al Malki, Monzr M.
Mei, Matthew
Ali, Haris
Spielberger, Ricardo
O’Donnell, Margaret
Snyder, David
Slavin, Thomas
Nakamura, Ryotaro
Stein, Anthony S.
Forman, Stephen J.
Marcucci, Guido
Pullarkat, Vinod
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
title Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
title_full Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
title_fullStr Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
title_full_unstemmed Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
title_short Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
title_sort therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165794/
https://www.ncbi.nlm.nih.gov/pubmed/29903756
http://dx.doi.org/10.3324/haematol.2018.193599
work_keys_str_mv AT aldossibrahim therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT stillertracey therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT tsainichun therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT songjooy therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT caothai therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT bandaranachini therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT salhotraamandeep therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT khaledsamer therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT aribiahmed therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT almalkimonzrm therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT meimatthew therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT aliharis therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT spielbergerricardo therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT odonnellmargaret therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT snyderdavid therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT slavinthomas therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT nakamuraryotaro therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT steinanthonys therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT formanstephenj therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT marcucciguido therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients
AT pullarkatvinod therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients